Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ATOMO DIAGNOSTICS LIMITED Earnings Release 2025

Oct 23, 2024

64440_rns_2024-10-23_4b8055ea-2cfd-48f3-aa88-b11c226c804a.pdf

Earnings Release

Open in viewer

Opens in your device viewer

24 October 2024

==> picture [75 x 72] intentionally omitted <==

ASX Announcement

Atomo Investor Webinar Presentation

SYDNEY Australia, 24 October 2024 – Atomo Diagnostics Limited (ASX: AT1 ) ( Atomo or the Company ) will release its Q1 FY25 Results on Tuesday 29[th] October 2024.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly will be held on Tuesday, 29th October 2024 at 2pm (AEDT).

To access the webinar please pre-register by clicking this link.

Please submit any questions in advance of the webinar commencing to: [email protected]

~ ENDS ~

For more information, please contact:

John Kelly Investor Queries Managing Director & CEO [email protected] e. [email protected] p. +61 401 922 279

This announcement was authorised by the Managing Director & CEO on behalf of the Board.

About Atomo

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com

Level 1, 3-5 George St Leichhardt NSW 2040

Atomo Diagnostics Limited ACN 142 925 684